<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Azanucleoside DNA-hypomethylating agents have remarkable clinical activity in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), particularly at low, non-cytotoxic doses favoring hypomethylation over cytotoxicity </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e>/testis antigens (CTAs) encoding immunogenic proteins are not expressed in almost <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_458'>normal</z:mpath> tissues and many <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types, but are consistently derepressed by epigenetically active agents in various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>Since the expression of CTA genes is usually very low or absent in myeloid <z:hpo ids='HP_0001909'>leukemias</z:hpo>, we treated various <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell lines with <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi> (DAC) and quantified <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of the CTAs NY-ESO-1, MAGEA1, MAGEA3 and MAGEB2 </plain></SENT>
<SENT sid="3" pm="."><plain>Consistent time- and dose-dependent reactivation of <z:hpo ids='HP_0000001'>all</z:hpo> 4 CTA genes was observed, with maximum <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels 72-144h after treatment start </plain></SENT>
<SENT sid="4" pm="."><plain>As determined by <z:chebi fb="40" ids="33697">RNA</z:chebi> microarray analyses, numerous other CTA genes (<z:hpo ids='HP_0000001'>all</z:hpo> located on the X-chromosome) were also derepressed in a time-dependent fashion by DAC </plain></SENT>
<SENT sid="5" pm="."><plain>NY-ESO-1 derepression was confirmed at the protein level </plain></SENT>
<SENT sid="6" pm="."><plain>By Elispot and <z:chebi fb="74" ids="28073">chromium</z:chebi> release assays we showed that the de novo expressed NY-ESO-1 protein was naturally processed and presented in a time- and dose-dependent fashion up to 8 days after the start of DAC treatment, and converted the cell lines susceptible to antigen-specific recognition by CD8+ T-cell clones </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, NY-ESO-1 and numerous other CTAs localized on the X-chromosome are readily and transiently derepressed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell lines treated with DAC </plain></SENT>
<SENT sid="8" pm="."><plain>The susceptibility of DAC-treated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell lines to antigen-specific T-cell recognition has clear implications for future clinical trials combining DAC and specific immunotherapy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>